Britain’s Frontier Pharma and the Baystone Investment Group have acquired Serbian pharmaceuticals company Zdravlje Leskovac, which is owned by Actavis, a subsidiary of Israeli company Teva. Baystone Group and Frontier Pharma are expected to further invest in Zdravlje Leskovac production and bring additional products to the facility over time.
BDK Advokati advised Frontier Pharma and Baystone Investment Group on this transaction. The closing is expected in the March 2021.
BDK Advokati transactional team was led by senior partner Vladimir Dašić, accompanied by associate Jelena Zelenbaba and junior associate Sanja Dedović. Managing partner Tijana Kojović and senior associate Bisera Andrijašević advised on the regulatory aspects of the transaction.
